Synthesis and in vitro cytotoxic activity of N-, F-, and S-ether derivatives of podophyllotoxin fatty acid adducts

Lipids

Volumn 40, Issue 4, 2005, Pages 375-382

  Mustafa, Jamal ^a   Khan, Shabana I ^a   Ma, Guoyi ^a   Walker, Larry A ^a,b   Khan, Ikhlas A ^a,b,c  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CYTOLOGY; DERIVATIVES; ETHERS; HYDROGENATION; NUCLEAR MAGNETIC RESONANCE; SPECTROSCOPIC ANALYSIS; SYNTHESIS (CHEMICAL); TOXICITY; TUMORS;

ANTITUMOR EVALUATION; CYTOTOXIC ACTIVITY; GROWTH INHIBITION; PODOPHYLLOTOXIN;

FATTY ACIDS;

4 O PODOPHYLLOTOXINYL 12 HYDROXYOCTADEC 9 ENOATE; 4 O PODOPHYLLOTOXINYL UNDEC 10 ENOATE; ANTINEOPLASTIC AGENT; CARBAMIC ACID DERIVATIVE; DOXORUBICIN; ETHER DERIVATIVE; FATTY ACID DERIVATIVE; FLUORINE DERIVATIVE; HYDROXYL GROUP; NITROGEN DERIVATIVE; PACLITAXEL; PODOPHYLLOTOXIN DERIVATIVE; SULFUR DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CARBON NUCLEAR MAGNETIC RESONANCE; CELL STRAIN HL 60; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROGENATION; IN VITRO STUDY; INFRARED SPECTROSCOPY; LEUKEMIA; MASS SPECTROMETRY; MELANOMA; MOUTH CARCINOMA; NONHUMAN; OVARY CARCINOMA; PROTON NUCLEAR MAGNETIC RESONANCE; VERO CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CERCOPITHECUS AETHIOPS; CYTOTOXINS; ETHERS; FATTY ACIDS; HUMANS; PODOPHYLLOTOXIN; VERO CELLS;

CERCOPITHECUS AETHIOPS; MAMMALIA;

EID: 20044376680     PISSN: 00244201     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11745-006-1397-x     Document Type: Article

References (30)

1. Kauffman, J.M., and Foye, W.O. (1981) Cancer Chemotherapy, in Principles of Medicinal Chemistry (Foye, W.O., ed.), pp. 837-861, Lea and Febiger, Philadelphia.
2. Haskel, C.M. (1990) Principles of Cancer Chemotherapy, in Cancer Treatment (Haskel, C.M., ed.), pp. 27-52, W.B. Saunders, Philadelphia.
3. Xi, C.W., and Wang, P.G. (2003) Glucuronides in Anti-cancer Therapy, Curr. Med. Chem.-Anti-cancer Agents 3, 139-150.
4. Gordaliza, M., Castro, M.A., Miguel del Correl, J.M., and Feliciano, A.S. (2000) Antitumor Properties of Podophyllotoxin and Related Compounds, Curr. Pharm. Design 6, 1811-1839.
5. Damayanthi, Y., and Lown, J.W. (1998) Podophyllotoxins: Current Status and Recent Developments, Curr. Med. Chem. 5, 205-252.
6. Jardine, I. (1980) Podophyllotoxin, in Anticancer Agents Based on Natural Product Models (Cassady, J.M., and Douras, J.D., eds.), pp. 319-351, Academic Press, New York.
7. Keller-Juslen, C., Kuhn, M., Stahelin, H., and von Wartburg, A. (1971) Synthesis and Antimitotic Activity of Glycosidic Lignan Derivatives Related to Podophyllotoxin, J. Med. Chem. 14, 936-940.
8. Issell, B.F., Muggia, P.M., and Carter, S.K. (eds.) (1984) Etoposide (VP-16): Current Status and New Developments, Academic Press, New York.
9. van Maanen, J.M.S., Retel, J., De Vries, J., and Pinedo, H.M. (1988) Mechanism of Action of the Antitumor Drug Etoposide, J. Natl. Cancer Inst. 80, 1526-1533.
10. Lee, K.H. (1999) Novel Anticancer Agents from Higher Plants, Med. Res. Rev. 19, 569-596.
11. Murdter, T.E., Sperker, B., Kivisto, K.T., McClellan, M., Fritz, P., Friedel, G., Under, A., Bosslet, K., Toomes, H., Dierkesmann, R., and Kroemer, H.K. (1997) Enhanced Uptake of Doxorubicin into Bronchial Carcinoma: β-Glucuronidase Mediates Release of Doxorubicin from Glucuronide Prodrug (HMR 1826) at the Tumor Site, Cancer Res. 57, 2440-2445.
12. Menendez, J.A., Ropero, S., Lupu, R., and Colomer, R. (2004) ω-6 Polyunsaturated Fatty Acid γ-Linolenic Acid (18:3n-6) Enhances Docetaxel (Taxotere) Cytoxicity in Human Breast Carcinoma Cells: Relationship to Lipid Peroxidation and HER-2/neu Expression, Oncol. Rep. 11, 1241-1252.
13. Moyer, M.P., Hardman, W.E., and Cameron, I. (2003) Accelerated Action Fatty Acid (AAFA) Promotes Health of Normal Tissues and Minimizes the Toxic Side Effects of Chemotherapy, U.S. Patent Application 2002-102907 200220322, Priority: US 2001-278138, 27pp.
14. Hardman, W.E., Cameron, I.L., and Moyer, M.P. (2001) Fatty Acids to Minimize Cancer Therapy Side Effects, PCT Intl. Application WO 99-US16666 19990722, 31 pp.
15. Larsson, S.C., Kumlin, M., Ingelman-Sundberg, M., and Wolk, A. (2004) Dietary Long-Chain n-3 Fatty Acids for the Prevention of Cancer: A Review of Potential Mechanisms, Am. J. Clin. Nutr. 79, 935-945.
16. Conklin, K.A. (2002) Dietary Polyunsaturated Fatty Acid: Impact on Cancer Chemotherapy and Radiation, Altern. Med. Rev. 7(1), 4-21.
17. Bougnoux, P. (1999) n-3 Polyunsaturated Fatty Acids and Cancer, Curr. Opin. Clin. Nutr. Metabol. Care 2, 121-126.
18. Berge, R. (2002) Fatty Acid Analogues for the Treatment of Cancer, PCT Intl. Application WO 2001-NO301 20010713, 31 pp.
19. Nagao, Y., Mustafa, J., Sano, S., Ochiai, M., Tazuko, T., and Shigeru, T. (1991) Different Mechanism of Action of Long Chain Fatty Acid Esters of Podophyllotoxin and Esters of Epipodophyllotoxin Against P388 Lymphocytic Leukemia in Mice, Med. Chem. Res. 1, 295-299.
20. Lie Ken Jie, M.S.F., Mustafa, J., and Pasha, M.K. (1999) Synthesis and Spectral Characteristics of Some Unusual Fatty Esters of Podophyllotoxin, Chem. Phys. Lipids 100, 165-170.
21. Mustafa, J., Khan, S.I., Ma, G., Walker, L.A., and Khan, I.A. (2004) Synthesis and Anticancer Activities of Fatty Acid Analogs of Podophyllotoxin, Lipids 39, 167-172.
22. Mustafa, J., Khan, S.I., Ma, G., Walker, L.A., and Khan, I.A. (2004) Synthesis, Spectroscopic and Biological Studies of Novel Estolides Derived from Antitumor Active 4-O-Podophyllotoxinyl 12-Hydroxyl Octadec-Z-9-enoate, Lipids 39, 659-666.
23. Ma, G., Khan, S.I., Mustafa, J., Walker, L.A., and Khan, I.A. (2005) Anticancer Activity and Possible Mode of Action of 4-O-Podophyllotoxinyl 12-Hydroxyl-octadec-Z-9-enoate, Lipids 40, 303-308.
24. Field, C.J., and Schley, P.D. (2004) Evidence for Potential Mechanisms for the Effect of Conjugated Linoleic Acid on Tumor Metabolism and Immune Function: Lessons from n-3 Fatty Acids, Am. J. Clin. Nutr. 79 (6 Suppl.), 1190S-1198S.
25. Akihisa, T., Tokuda, H., Ogata, M., Ukiya, M., Iizuka, M., Suzuki, T., Metori, K., Shimizu, N., and Nishino, H. (2004) Cancer Chemopreventive Effects of Polyunsaturated Fatty Acids, Cancer Lett. 205, 9-13.
26. Fearon, K.C.H. (2002) The Anticancer and Anticachectic Effects of n-3 Fatty Acids, Clin. Nutr. 21 (Suppl. 2), S73-S77.
27. Tronstad, K.J., Berge, K., Berge, R.K., and Bruserud, O. (2003) Modified Fatty Acids and Their Possible Therapeutic Targets in Malignant Diseases, Expert Opin. Ther. Targets 7, 663-677.
28. Stelzer, U., and Effenberger, F. (1993) Preparation of (S)-Fluoronitriles, Tetrahedron Asymm. 4, 161-164.
29. Focella, A., Bizzarro, F., and Exon, C. (1991) Simple Stereospecific Syntheses of (R)-Fluorohexanoic Acid Ethyl Ester, Synth. Commun. 21, 2165-2170.
30. Leroy, J., Hebert, E., and Wakselman, C. (1979) Maximum Optical Rotation of 2-Fluorooctane? Survey of Fluorinating Reagents, J. Org. Chem. 44, 3406-3408.